ReviewSignal transduction and targeted therapy2022

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Xiaohan Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.